The global Fusion biopsy market is anticipated to grow at a CAGR of 8.4% during the forecast period (2023-2030). The global Fusion biopsy market is anticipated to grow at a significant rate owing to several factors which includes, improved diagnostic accuracy, increasing focus on early detection and personalized treatment and rising prevalence of prostate cancer. Prostate cancer is the most common cancer among men (after skin cancer), but it can often be treated successfully. According to world cancer research fund international, there were an estimated 18.1 million cancer cases around the world in 2020. Of these, 9.3 million cases were in men and 8.8 million in women. And Prostate cancer is the 2nd most commonly occurring cancer in men and the 4th most common cancer overall. There were more than 1.4 million new cases of prostate cancer in 2020.
Browse the full report description of “Fusion biopsy Market Size, Share & Trends Analysis Report by Biopsy Route (Transrectal and Transperineal), and by End User (Hospitals, Diagnostic Centers and Ambulatory Care Centers), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/fusion-biopsy-market
In April 2023, UC San Diego Health is the first health system in San Diego County to offer a new minimally invasive prostate biopsy procedure that reduces the risk of infection, improves imaging for accuracy and may increase cancer detection in a clinic setting. Called a transperineal biopsy, the procedure is combined with 3D MRI fusion guided technology to highlight prostate cancer. It is the latest urological cancer diagnostic tool to be added to an extensive list of innovative resources used for diagnosing cancer at UC San Diego Health. Traditionally, a transrectal biopsy was the standard procedure to test for prostate cancer if a prostate-specific antigen blood test was elevated and/or a digital rectal exam was flagged.
In January 2023, aiming to revolutionise prostate cancer detection and treatment, Apollo Hospital Seshadripuram has introduced a novel technology, MRI Fusion TRUS guided Trans-Perineal Targe¬ted Biopsy, that enhances the accuracy of cancer detection by 95 to 97%. “In this procedure, one has to undergo multi-parametric MRI and contouring of the lesions which are suspected to be cance¬rous, and prostate size is marked via a special software pack.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Biopsy Route
o By End-use
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes, Eigen Health, ESAOTE SpA, Focal Healthcare, GeoScan Medical, Hitachi Ltd., KOELIS, Koninklijke Philips N.V., MedCom, UC-Care Medical Systems Ltd., and others.
Key questions addressed by the report
Global Fusion biopsy Market Report Segment
By Biopsy Route
By End-use
Global Fusion biopsy Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/fusion-biopsy-market